Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / Aisling Capital Management LP
Form 13F · Q2 2026

Aisling Capital Management LP

CIK 1766721Filed 2026-08-1313F-HR View the filing on EDGAR ↗
$472M
Reported book value
14
Positions
12
Quarters on record
Top 50
Positions

Aisling Capital Management LP — holdings

Top 14 positions of 14, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1BBIO Bridgebio Pharma Inc4.6M−9.8%$342M72.5%
2GLUE Monte Rosa Therapeutics Inc1.6M+0.0%$38M8.0%
3SNDX Syndax Pharmaceuticals Inc1.3M+0.0%$29M6.1%
4CMPS Compass Pathways Plc1.4M+0.0%$20M4.3%
5BCAX Bicara Therapeutics Inc568,919+0.0%$17M3.6%
6BBOT Bridgebio Oncology Therapeut1.0M+0.0%$8M1.6%
7SRRK Scholar Rock Hldg Corp77,031+0.0%$4M0.9%
8URGN Urogen Pharma Ltd108,000+0.0%$4M0.8%
9BMEA Biomea Fusion Inc2.0M+0.0%$3M0.6%
10ACRS Aclaris Therapeutics Inc434,455+0.0%$2M0.5%
11EPRX Eupraxia Pharmaceuticals Inc325,000+0.0%$2M0.5%
12VTVT Vtv Therapeutics Inc50,000—$2M0.4%
13MRKR Marker Therapeutics Inc325,370+0.0%$478,2930.1%
14OKUR Onkure Therapeutics Inc88,607+0.0%$404,0480.1%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.